Why the study?
Do ergot-derived dopamine agonists (pergolide or cabergoline) increase the risk of clinically important valve regurgitation in patients with Parkinson's disease compared to non-ergot derivatives or controls?
Do ergot-derived dopamine agonists (pergolide or cabergoline) increase the risk of clinically important valve regurgitation in patients with Parkinson's disease compared to non-ergot derivatives or controls?
Ergot-derived dopamine agonists (pergolide and cabergoline) are associated with a significantly increased risk of clinically important valve regurgitation, which should be considered when evaluating their risk-benefit ratio.
Ergot-derived agents were associated with regurgitation risk; leaves open whether non-ergot derivatives are preferable pending prospective data in Parkinson's disease.
The frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide or cabergoline, but not in patients taking non-ergot-derived dopamine agonists, as compared with control subjects. These findings should be considered in evaluating the risk-benefit ratio of treatment with ergot derivatives.
No takes yet. Share an insight, caveat, or question.
Zanettini et al. (2007) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: